Jeil Pharma Holdings Inc (KRX:002620)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,450.00
+100.00 (1.36%)
Oct 2, 2026, 3:30 PM KST

Jeil Pharma Holdings Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
610,332633,700769,968794,714787,256756,633
Other Revenue
20,55923,9149,8559,3295,7085,935
630,891657,614779,822804,043792,965762,568
Revenue Growth
-14.26%-15.67%-3.01%1.40%3.99%0.07%
Cost of Revenue
374,201404,116573,301589,459612,482582,061
Gross Profit
256,690253,498206,521214,584180,483180,507
Selling, General & Admin
174,964167,068158,715146,364146,465149,808
Research & Development
59,22745,20338,95046,03841,56639,673
Other Operating Expenses
1,7011,68220,7191,363--
Operating Expenses
238,080214,512217,702193,664188,031189,482
Operating Income
18,61038,986-11,18120,920-7,548-8,975
Interest Expense
-7,399-7,494-8,875-10,672-5,952-3,289
Interest & Investment Income
2,0961,9482,4564,119508.95256.81
Earnings From Equity Investments
808.35808.35---2,516
Currency Exchange Gain (Loss)
5,504-140.063,019-169.48314.8816.09
Other Non Operating Income (Expenses)
-11.0269.9-7,435-2,492856.19-2,864
EBT Excluding Unusual Items
19,60934,178-22,01611,706-11,820-11,539
Impairment of Goodwill
---44,862-28,604-78,335-17,014
Gain (Loss) on Sale of Investments
5,2495,3795,9072,9237,12720,876
Gain (Loss) on Sale of Assets
912.087.970.5323.981,930
Asset Writedown
-204.32-204.32-662.52-7.42-856.39-382
Pretax Income
24,66239,365-61,626-13,982-83,861-6,129
Income Tax Expense
-759.634,7184,765-740.82-715.626,741
Earnings From Continuing Operations
25,42234,647-66,391-13,241-83,145-12,870
Net Income to Company
25,42234,647-66,391-13,241-83,145-12,870
Minority Interest in Earnings
-16,987-20,01215,232-3,0098,5899,388
Net Income
8,43514,635-51,159-16,250-74,556-3,482
Net Income to Common
8,43514,635-51,159-16,250-74,556-3,482
Net Income Growth
------
Shares Outstanding (Basic)
151515151515
Shares Outstanding (Diluted)
151515151515
Shares Change
-0.04%0.01%-0.01%---
EPS (Basic)
549.45953.37-3333.00-1058.54-4856.70-226.85
EPS (Diluted)
549.37953.37-3333.00-1059.00-4857.00-227.00
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-902.83-7,893202.38-10,638-32,717-10,284
Free Cash Flow Per Share
-58.81-514.1813.19-692.99-2131.27-669.95
Dividend Per Share
---50.00050.00065.000
Dividend Growth
---0%-23.08%-7.14%
Gross Margin
40.69%38.55%26.48%26.69%22.76%23.67%
Operating Margin
2.95%5.93%-1.43%2.60%-0.95%-1.18%
Profit Margin
1.34%2.23%-6.56%-2.02%-9.40%-0.46%
Free Cash Flow Margin
-0.14%-1.20%0.03%-1.32%-4.13%-1.35%
EBITDA
33,94753,9352,91833,4763,3578.31
EBITDA Margin
5.38%8.20%0.37%4.16%0.42%0.00%
D&A For EBITDA
15,33714,94914,09912,55610,9058,983
EBIT
18,61038,986-11,18120,920-7,548-8,975
EBIT Margin
2.95%5.93%-1.43%2.60%-0.95%-1.18%
Effective Tax Rate
-11.99%----
Advertising Expenses
-7,9749,5975,9296,2288,742